Ligand Pharmaceuticals
LGND Mid CapHealthcare · Biotechnology
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and childre
Ligand Pharmaceuticals Stock at a Glance
Ligand Pharmaceuticals (LGND) is currently trading at $320.42 with a market capitalization of $6.4B. The trailing P/E ratio stands at 41.78x, with a forward P/E of 28.31x. The 52-week range spans from $112.83 to $322.31; the current price is 0.6% below the yearly high. Year-over-year revenue growth stands at +14.1%. The net profit margin stands at 55.95%.
💰 Dividend
Ligand Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
10 analysts rate Ligand Pharmaceuticals (LGND) on consensus: Strong Buy. The average price target is $277.60, implying -13.36% from the current price. Analyst price targets range from $247.00 to $330.00.
Ligand Pharmaceuticals: The Investment Case in Detail
Ligand Pharmaceuticals (LGND) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Revenue is growing at a healthy 14.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 83.16%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 55.95%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
The Bear Case
Short interest sits at 10.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valuation in Context
The EV/EBITDA multiple of 45.2x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
What to Watch Next
- The forward P/E of 28.31x is meaningfully below the trailing 41.78x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 99.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Profitable with 55.95% net margin
- High return on equity (17.13% ROE)
- High gross margin of 83.16% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 45.32)
- Positive free cash flow
- –Currently flagged as overvalued
- –High short interest (10.1%)
- –Price near 52-week high — limited upside cushion
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (10.1%).
Trading Data
Related Stocks in the Same Sector
Ligand Pharmaceuticals 2026: Royalty Pharma Compounder, Filspari + CAPVAXIVE Acceleration and the 47-Employee Asset-Light Model
The Real Story
Ligand Pharmaceuticals is the smaller and more deal-flow-focused alternative to Royalty Pharma in the US-listed biopharmaceutical royalty-aggregator category. The business model is extraordinary in its operational simplicity: 47 total employees, no in-house drug development or commercialisation, no manufacturing, no sales force — pure royalty rights and milestone-payment receivables on 100+ active partnered biopharmaceutical assets. FY2025 revenue USD 274 M (+14.1% growth), gross margin 83.2%, operating margin 33.6%, profit margin 55.95% — among the highest specialty-biotech profitability profiles globally because there is no commercial-execution cost burden. Free cash flow USD 142 M, EPS USD 7.66 on 20 million share count, P/E 27.8x and forward P/E 18.8x.
The 2026 strategic story has three threads. First, the launch-stage royalty stream is accelerating: Filspari (Travere Therapeutics, IgA nephropathy) ramped to USD 70 M annual royalty pace by end-2025 from launch in 2024, with potential FSGS label expansion in 2026 doubling the addressable market. CAPVAXIVE (Merck, 21-valent pneumococcal conjugate vaccine) launched 2025 and is taking adult-vaccine share from Prevnar 20 (Pfizer) — Ligand's royalty exposure grows as CAPVAXIVE ramps from USD 250 M (2025) toward USD 1.5+ bn (2028 peak). Combined Filspari + CAPVAXIVE royalty contribution grows from USD 100 M to USD 250-300 M by 2028. Second, the Kyprolis royalty step-down: Kyprolis (Amgen multiple myeloma) is Ligand's largest single royalty (approximately USD 80 M annual) but contractually steps down post-2027 — this is the headline bear concern and the multi-year transition to new-launch royalty growth is the key thesis. Third, the bolt-on royalty acquisition pipeline: Ligand acquired Pelican BioPharma in late 2024 for USD 235 M, adding royalty rights on multiple Phase 3 and approved assets; the management team's expertise is identifying and pricing royalty deals at attractive returns.
The 2026 question is whether Filspari label expansion and CAPVAXIVE adult-vaccine share-take fully offset the Kyprolis royalty step-down by 2028, whether the bolt-on M&A pipeline continues delivering 15-20% IRR on deployed capital, and whether the asset-light high-margin model continues to attract investors at the 18.8x forward P/E that prices it as a quality compounder.
What Smart Money Thinks
Top holders Q1/2026: Vanguard 9.2%, BlackRock 7.6%, T. Rowe Price 4.5%, FMR (Fidelity) 3.4%, State Street 3.1%, Wellington Management 2.8%, Renaissance Technologies 2.0%. Free-float effectively 90% with no founder-block or major active institutional concentration above 5%.
Most interesting move: T. Rowe Price increased its position 18% in Q4/2025 — continuing the multi-year accumulation of LGND as a quality-compounding healthcare-royalty position. Wellington added 24% in Q1/2026. Renaissance Technologies opened a fresh 2.0% position in Q1/2026 — quantitative momentum entry coinciding with the share-price normalisation from the EUR 247 peak. The holder base is unusually high-quality for a small-cap biotech — heavy on long-duration fundamental investors rather than yield-focused or speculative holders.
Insider activity: CEO Todd Davis (in role since 2022, ex-Royalty Pharma co-founder and managing partner) made no open-market purchases in 2024-2025 — standard restraint pattern given high-percentage equity compensation. CFO Matthew Korenberg exercised options in Q4/2025 and held 80% of resulting shares. President and CSO Matt Foehr (longest-tenured executive, with Ligand since 2011) has not transacted since 2023. Notably, Davis's USD 2.4 M of unvested equity from his joining package fully vests by 2027 — an alignment incentive structure that ties his economic interest to multi-year share-price performance.
Short interest 8.7% (short ratio 6.5 days to cover) — moderate. The bear thesis is concentrated on Kyprolis royalty step-down 2027 impact, Pelican BioPharma acquisition price scrutiny, and the inherent lumpiness of royalty revenue from non-cash items (warrant valuations, milestone-payment timing, contingent-consideration adjustments).
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Filspari (Travere Therapeutics, IgA nephropathy) ramped to USD 70 M annual royalty pace by end-2025 from launch 2024. FSGS label expansion expected H2/2026 doubles addressable market. CAPVAXIVE (Merck pneumococcal vaccine) launched 2025 with strong adult-vaccine share-take from Prevnar 20 — Ligand royalty exposure grows from approximately USD 30 M (2025) to USD 80-120 M by 2028 peak. Combined growth in Filspari + CAPVAXIVE royalty contribution from USD 100 M to USD 200-300 M by 2028 fully offsets the Kyprolis post-2027 step-down (worth approximately USD 80 M annual). The transition from one mature blockbuster royalty to two ramping specialty royalties is the structural-growth thesis.
Ligand operates the most asset-light biopharmaceutical-royalty model in the US listed space — 47 employees, no commercial infrastructure, no manufacturing, no clinical-development cost burden. Operating margin 33.6%, profit margin 55.95%, free cash flow USD 142 M on USD 274 M revenue (52% FCF-to-revenue conversion). This model scales with no capital reinvestment requirement — every dollar of new royalty deal flow drops 50%+ to free cash flow. The structural margin advantage is sustainable because Ligand does not face the cost-of-goods-sold or sales-force inflation pressures that compress commercial biotech margins.
Ligand acquired Pelican BioPharma in Q4/2024 for USD 235 M cash, adding royalty rights on multiple Phase 3 and approved assets (including Pradefovir, Posaconazole). The management team's expertise is identifying and pricing royalty deals at attractive returns — typically 15-20% IRR on deployed capital. The royalty-acquisition market has expanded significantly with sustained venture-capital-backed biotech needing non-dilutive financing — annual deal flow estimated at USD 4-6 bn globally. Ligand's combination of speed, structuring expertise and balance-sheet capacity (USD 200 M+ cash + USD 300 M undrawn credit) positions it to capture 5-10% of that deal flow.
📉 The 3 Real Bear Points
Kyprolis (Amgen, multiple myeloma) is currently Ligand's largest single royalty at approximately USD 80 M annual. The contractual rate steps down post-2027 in a structure tied to the underlying licensing agreement. The 2027-2029 transition period requires Filspari + CAPVAXIVE + new bolt-on royalties to fully replace Kyprolis economics. Bears argue the timing is tight: even if Filspari and CAPVAXIVE deliver as modelled, the 2027-2028 reported earnings could decline 5-10% from current levels before resuming growth in 2029-2030. A growth pause in a high-multiple stock is a multiple-compression risk.
The USD 235 M Pelican BioPharma acquisition (Q4/2024) was the largest in Ligand's history. Several analyst notes question whether Ligand paid full price for Phase 3 assets that have not yet de-risked clinically. If Pelican-acquired assets do not deliver the modelled USD 35-50 M annual royalty contribution by 2027, the deal IRR drops below the management-targeted 15-20%, raising questions about future capital-allocation discipline. Pelican was sold by RTW Investments, a sophisticated biotech specialist — and Ligand was the only public acquirer, which some interpret as a price-discovery negative.
Royalty revenue includes both contractual cash payments and non-cash items (warrant fair-value adjustments, milestone-payment timing, contingent-consideration revaluations). Quarterly earnings can swing meaningfully from one quarter to the next based on accounting timing. The Q2/2025 reported earnings beat was partly driven by an upward warrant revaluation that subsequently reversed in Q4 — confusing market signals. Ligand has not reformed its reporting framework to provide clean cash-royalty disclosure; bears argue this opacity is a corporate-governance issue.
Valuation in Context
Forward P/E 18.8x, P/S 15.6x, EV/EBITDA 30.2x. P/S is high but reflects the asset-light high-margin model. The right valuation framework is multi-year royalty-stream NPV: Kyprolis (USD 80 M annual through 2027, USD 40-50 M post-2028), Filspari (USD 70 M annual ramping to USD 150-200 M by 2028), CAPVAXIVE (USD 30 M ramping to USD 80-120 M by 2028), legacy long-tail royalties (USD 50-80 M annual stable). Total normalised 2028 royalty USD 350-450 M, NPV USD 3.5-5.0 bn. Pelican plus future bolt-ons potentially add USD 1.0-1.5 bn. Total NPV USD 5-6 bn versus current market cap USD 4.3 bn — modest upside on base case. Sell-side PT consensus USD 271.80 (range USD 220-330): Mizuho most bullish at USD 330 (Filspari peak + CAPVAXIVE share take + Pelican delivers + bolt-ons compound), B. Riley most bearish at USD 220 (Kyprolis step-down full impact + Pelican below model + bolt-on slowdown). 10 analysts cover, recommendation strong-buy. Implied probability of base-case execution in current price approximately 60%. Bull case USD 320 (+50%) on all three growth drivers delivering. Bear case USD 165 (-23%) on Kyprolis impact + Pelican disappoints.
🗓️ Next 3 Catalyst Dates
- Q2 2026: Q1/2026 results — Filspari and CAPVAXIVE royalty trajectory + bolt-on M&A pipeline update
- H2 2026: Filspari FSGS label expansion FDA decision — potential 2x addressable market
- Q1 2027: FY2026 results + 2027 guidance — defines Kyprolis transition trajectory
💬 Daniel's Take
Ligand Pharmaceuticals is the cleanest high-quality asset-light biopharmaceutical-royalty compounder in the US small-cap biotech space. The thesis is straightforward: 47-employee operating model, 33% operating margin, 56% profit margin, multi-year royalty growth from Filspari and CAPVAXIVE offsetting Kyprolis step-down, and an active bolt-on M&A pipeline that compounds the capital base at 15-20% IRR. The 2027 Kyprolis transition is a real concern but is a known headwind that management has been positioning for since 2022. At 18.8x forward P/E, I am paying a quality-compounder multiple for a structurally advantaged business model. I size LGND at 1.5-2.5% as the high-quality biotech-royalty satellite position. The trade I would not make is sizing above 3% — the 2027 Kyprolis-step-down execution risk and the Pelican-deal scrutiny are not zero and concentrate the bear case in narrow time windows. Add trigger: Filspari FSGS label approval + any quarter with CAPVAXIVE royalty above USD 12 M. Cut trigger: Filspari label expansion delays or any bolt-on deal at less-than-15% modelled IRR. This is a 3-5 year compounding hold — the patience is the price of admission to 12-15% IRR on a defensive cash-flow-generative business.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Ligand Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news